Fort Lee, NJ, April 10, 2023 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the initiation of the Phase 1b…Read More
Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in PlatinumResistant ARID1aMutated Ovarian Carcinoma
